Abstract:Abstract Background: Eliminating HIV vertical transmission (VT) and is a global priority. Estimates of paediatric HIV infections are commonly derived through mathematical models relying on rates of VT stratified by maternal immunological and treatment status from literature, namely the UNAIDS-supported Spectrum AIDS Impact Module (Spectrum-AIM) to assess progress towards eliminating VT. Default VT probabilities were last updated in 2018, since then there have been substantial changes to service delivery and ART regimens. Methods: We aimed to (1) update the systematic review of VT probabilities by maternal status compatible with Spectrum-AIM, (2) conduct a meta-regression to systematically pool studies to estimate VT probabilities with statistical uncertainty, and (3) assess determinants of VT, including maternal viral load. We searched PubMed, Embase, Global Health Database, WHO Global Index Medicus, CINAHL Complete, and Cochrane CENTRAL for peer-reviewed articles in English from all geographic regions with data on VT from randomized controlled trials, cohort studies, or observational studies. We excluded sources that did not stratify VT by maternal treatment or immunological status. We fit four meta-regression models to produce VT probability estimates compatible with stratifications used in Spectrum-AIM and assessed how updated VT probabilities estimated new paediatric infections compared to default parameters in Spectrum-AIM. We conducted subgroup analyses to assess how study inclusion affected model estimates. Finally, we fit a meta-regression model to assess ART class and initiation timing on viral load suppression at delivery. Findings: The updated systematic review identified 24 new studies published between January 2018 and February 2024. Combined with previous review data, 110 studies were included in the meta-regression analysis. Estimates were broadly consistent with previous reviews. For women not receiving PMTCT, the odds of perinatal transmission decreased by 0.20 (0.16-0.25) for each 100 mm3 increase in median CD4 of the study population. Among women on ART during pregnancy, each additional week on ART before delivery reduced the odds of VT by 5.6% (4.3%-6.8%). ART regimen class affected VT probability; the odds ratio of perinatal VT among WLHIV who initiated an INSTI-based regimen versus a NNRTI-based regimen 20 weeks before delivery was 0.355 (0.140-0.898). However, this effect was confounded by study region. Viral load suppression at delivery was significantly lower among women who started ART late during pregnancy (p=0.02), but did not significantly differ by ART class (p>0.05). Interpretation: Vertical transmission rates vary substantially according to maternal immunological stage, prophylactic regimen, and timing of treatment initiation. Time of initiation on ART before delivery was strongly associated with viral load suppression at delivery. Our estimates and their uncertainty can be used in Spectrum-AIM to produce estimates of paediatric incidence to inform funding and monitor progress towards eliminating VT. Funding: National Institutes of Health, UNAIDS, and the Medical Research Council

Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial

Factors associated with vertical transmission of HIV in the Western Cape, South Africa: a retrospective cohort analysis

Prevention of vertical transmission of HIV in Khayelitsha, South Africa: A contemporary review of services after 20 years

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.

Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses

Emerging integrase resistance in an international perinatal virtual clinic

Impact of Human Immunodeficiency Virus Drug Resistance Mutations Detected in Women Prior to Antiretroviral Therapy With Efavirenz + Tenofovir Disoproxil Fumarate + Lamivudine (or Emtricitabine)

Mother-to-Child Transmission of HIV Within 24 Months After Delivery in Women Initiating Lifelong Antiretroviral Therapy Pre/Post-Conception or Postnatally; Effects of Adolescent Girl and Young Woman Status and Plasma Viremia Late in Pregnancy

Probability of vertical HIV transmission: A systematic review and meta-regression

HIV Drug Resistance in Newly Diagnosed Young Children in the Western Cape, South Africa

Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry Analysis

More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa

Sustained aviraemia despite anti-retroviral therapy non-adherence in male children following in utero hiv transmission

Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial

HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania

Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential

Analysis of Primary Resistance Mutations to HIV-1 Entry Inhibitors in Therapy Naive Subtype C HIV-1 Infected Mother–infant Pairs from Zambia

Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers

Clinical Pathological Characteristics and Survival of High-Grade Endometrioid Carcinoma

Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho